Monocyte/Macrophage‐Mediated Transport of Dual‐Drug ZIF Nanoplatforms Synergized with Programmed Cell Death Protein‐1 Inhibitor Against Microsatellite‐Stable Colorectal Cancer
Sign Up to like & getrecommendations! Published in 2024 at "Advanced Science"
DOI: 10.1002/advs.202405886
Abstract: Microsatellite‐stable colorectal cancer (MSS‐CRC) exhibits resistance to programmed cell death protein‐1 (PD‐1) therapy. Improving the infiltration and tumor recognition of cytotoxic T‐lymphocytes (CTLs) is a promising strategy, but it encounters huge challenges from drug delivery… read more here.
Keywords: crc; drug; tumor; zif ... See more keywords
Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-004302
Abstract: Backgrounds Proficient-mismatch-repair or microsatellite stability (pMMR/MSS) colorectal cancer (CRC) has limited efficacy for immune checkpoint blockade (ICB) therapy and its underlying mechanism remains unclear. Guanylate binding protein 2 (GBP2) is a member of the GTPase… read more here.
Keywords: gbp2; mss crc; cancer; crc ... See more keywords
Abstract 5056: Molecular characterization of microsatellite stable (MSS) colorectal cancer (CRC) patients with a BRAF V600E mutation
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-5056
Abstract: Introduction: A BRAFV600E mutation is an unfavorable prognostic biomarker for CRC and is associated with short-lived treatment response to BRAF and EGFR blockade. Anti-PD-1 therapies are ineffective in MSS CRC but demonstrate efficacy in combination… read more here.
Keywords: cancer; crc patients; crc; brafv600e ... See more keywords
A phase II, open label, randomized, noncomparative study of eFT508 (tomivosertib) alone or in combination with avelumab in subjects with relapsed/refractory microsatellite stable colorectal cancer (MSS CRC).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e14145
Abstract: e14145 Background: Dysregulated translation of messenger RNA (mRNA) plays a role in the pathogenesis of solid tumors. Tomivosertib (T), a potent and highly selective small molecule inhibitor of MNK-1 and 2 blocks activation of eIF4E,… read more here.
Keywords: part; combination; mss crc; phase ... See more keywords
Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.3597
Abstract: 3597 Background: There is a high unmet need for the treatment of patients [pts] with metastatic microsatellite stable colorectal cancer [MSS-CRC]. We reported encouraging preliminary antitumor activity with the combination of COM701 + nivolumab in… read more here.
Keywords: combination; antitumor activity; liver metastases; mss crc ... See more keywords
IDOV-Safe: An intravenously deliverable oncolytic vaccinia virus for solid tumors refractory to standard of care—preliminary results from the pMMR/MSS CRC cohort.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e15556
Abstract: e15556 Background: Metastatic pMMR/MSS colorectal cancer (CRC) remains challenging to treat following progression on oxaliplatin- and irinotecan- based therapies, with limited responsiveness to PD-1/PD-L1 inhibitors. Oncolytic viruses (OVs) offer a promising new approach to bio-immunotherapy… read more here.
Keywords: idov; pmmr mss; idov safe; phase ... See more keywords
Phase 1/2 study of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with advanced solid tumors and in MSS CRC.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.4_suppl.206
Abstract: 206 Background: XTX101 is an investigational tumor-activated, Fc-enhanced, high affinity binding aCTLA-4 designed to block CTLA-4 and deplete regulatory T cells upon activation in the tumor by proteases. XTX101 also contains mutations designed to enhance… read more here.
Keywords: combination; tumor; phase; xtx101 ... See more keywords
Phase II study of cabozantinib and nivolumab in refractory metastatic microsatellite stable (MSS) colorectal cancer (CRC).
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.4_suppl.229
Abstract: 229 Background: Current data suggest that combining tyrosine kinase inhibitors with immune checkpoint inhibitors may be a promising treatment strategy in patients with metastatic MSS CRC. This prospective, open-label, single-arm, phase II study (NCT04963283) evaluated… read more here.
Keywords: phase study; refractory; crc; patients metastatic ... See more keywords
Targeting Pin1 to overcome immunosuppressive tumor microenvironment in MSS colorectal cancer
Sign Up to like & getrecommendations! Published in 2025 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2025.1677029
Abstract: Background Management of the immunosuppressive tumor microenvironment (TME) is crucial for microsatellite stability (MSS) colorectal cancer (CRC), which responds poorly to immunotherapy. PIN1, a peptidyl-prolyl cis-trans isomerase that is overexpressed in human malignancies, regulates TME… read more here.
Keywords: cancer; crc; immunosuppressive tumor; mss ... See more keywords